Nanoformulation of a novel potent ebselen analog for treatment of vulvovaginal candidiasis supplementary dataset

<b>Background: </b>Vulvovaginal candidiasis is primarily caused by <i>Candida albicans </i>(<i>C. albicans</i>). Here, a novel organoselenium compound (G20) was synthesized and evaluated for anti-<i>Candida </i>activity. <b>Methods: </b>Growth-inhibition studies and medium acidification assays to assess the inhibition of the yeast plasma membrane H<b>+</b>-ATPase (Pma1p) were carried out <i>in vitro </i>using G20. A self-nanoemulsifying formulation (SNEP) of G20 was prepared and evaluated for antimycotic activity in a mouse model. <b>Results: </b>G20 inhibited the growth of <i>C. albicans </i>through a mechanism that, at least in part, involves the inhibition of Pma1p. The G20-SNEP formulation significantly reduced vaginal colonization and vaginal inflammation relative to yeast-infected but untreated control mice. <b>Conclusion: </b>G20-SNEP exhibits potent antimycotic activity in a mouse model of vulvovaginal candidiasis.